| Year |
Citation |
Score |
| 2018 |
Vitale LA, Thomas LJ, He L, O'Neill T, Widger J, Crocker A, Testa J, Sundarapandiyan K, Forsberg E, Boyer J, Storey J, Goldstein J, Marsh HC, Keler T. Abstract 5624: Development of novel bispecific immune modulating antibodies Cancer Research. 78: 5624-5624. DOI: 10.1158/1538-7445.Am2018-5624 |
0.365 |
|
| 2018 |
Thomas LJ, He L, Testa J, Wasiuk A, Weidlick J, Sisson C, Vitale LA, O'Neill T, Forsberg E, Pilsmaker CD, Gergel LE, Do EQ, Boyer J, Baronas AR, Rocheleau M, et al. Abstract 3816: Efficacy of CDX-1140, an agonist CD40 antibody, in preclinical tumor models Cancer Research. 78: 3816-3816. DOI: 10.1158/1538-7445.Am2018-3816 |
0.395 |
|
| 2017 |
Turaj AH, Hussain K, Cox KL, Rose-Zerilli MJJ, Testa J, Dahal LN, Chan HTC, James S, Field VL, Carter MJ, Kim HJ, West JJ, Thomas LJ, He LZ, Keler T, et al. Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. Cancer Cell. 32: 777-791.e6. PMID 29198913 DOI: 10.1016/J.Ccell.2017.11.001 |
0.439 |
|
| 2017 |
Wasiuk A, Testa J, Weidlick J, Sisson C, Vitale L, Widger J, Crocker A, Thomas LJ, Goldstein J, Marsh HC, Keler T, He LZ. CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy. Journal of Immunology (Baltimore, Md. : 1950). PMID 29109120 DOI: 10.4049/Jimmunol.1700606 |
0.442 |
|
| 2017 |
He L, Widger J, Testa J, Mills-Chen L, Zhao B, Weidlick J, Sisson C, Wasiuk A, Vitale L, Goldstein J, Marsh H, Keler T, Ramakrishna V. Abstract 3664: CDX-1402, a dendritic cell targeted fusion protein designed to elicit immunity to mesothelin and HER2 expressing tumors Immunology. 77: 3664-3664. DOI: 10.1158/1538-7445.Am2017-3664 |
0.311 |
|
| 2016 |
He L, Testa J, Anna W, Jeffery W, Sisson C, Vitale LA, O'Neill T, Crocker A, Widger J, Goldstein J, Marsh HC, Keler T. CDX-1140, a Novel Agonist CD40 Antibody with Potent Anti-Lymphoma Activity Blood. 128: 1848-1848. DOI: 10.1182/Blood.V128.22.1848.1848 |
0.446 |
|
| 2015 |
He L, Wasiuk A, Testa J, Weidlick J, Sisson C, Crocker A, Widger J, Forsberg E, Gergel L, Thomas L, Marsh H, Keler T. The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent Journal For Immunotherapy of Cancer. 3: 188. DOI: 10.1186/2051-1426-3-S2-P188 |
0.415 |
|
| 2014 |
Comber JD, Karabudak A, Shetty V, Testa JS, Huang X, Philip R. MHC Class I Presented T Cell Epitopes as Potential Antigens for Therapeutic Vaccine against HBV Chronic Infection. Hepatitis Research and Treatment. 2014: 860562. PMID 24971174 DOI: 10.1155/2014/860562 |
0.585 |
|
| 2013 |
He L, Thomas LJ, Testa J, Weidlick J, Sisson C, Hammond R, Vitale L, Marsh H, Keler T. Combination therapies augment the anti-tumor activity of agonist CD27 mAb in human CD27 transgenic mouse models Journal For Immunotherapy of Cancer. 1: 76. DOI: 10.1186/2051-1426-1-S1-P76 |
0.4 |
|
| 2012 |
Testa JS, Philip R. Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications. Future Virology. 7: 1077-1088. PMID 23630544 DOI: 10.2217/Fvl.12.108 |
0.507 |
|
| 2012 |
Testa JS, Shetty V, Hafner J, Nickens Z, Kamal S, Sinnathamby G, Philip R. MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response. Plos One. 7: e48484. PMID 23144892 DOI: 10.1371/Journal.Pone.0048484 |
0.576 |
|
| 2012 |
Shetty V, Nickens Z, Testa J, Hafner J, Sinnathamby G, Philip R. Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells. Journal of Proteomics. 75: 3270-90. PMID 22504797 DOI: 10.1016/J.Jprot.2012.03.044 |
0.339 |
|
| 2012 |
Testa JS, Shetty V, Sinnathamby G, Nickens Z, Hafner J, Kamal S, Zhang X, Jett M, Philip R. Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response. The Journal of Infectious Diseases. 205: 647-55. PMID 22246683 DOI: 10.1093/Infdis/Jir814 |
0.582 |
|
| 2011 |
Liu Y, Testa JS, Philip R, Block TM, Mehta AS. A ubiquitin independent degradation pathway utilized by a hepatitis B virus envelope protein to limit antigen presentation. Plos One. 6: e24477. PMID 21969857 DOI: 10.1371/Journal.Pone.0024477 |
0.402 |
|
| 2010 |
Testa JS, Apcher GS, Comber JD, Eisenlohr LC. Exosome-driven antigen transfer for MHC class II presentation facilitated by the receptor binding activity of influenza hemagglutinin. Journal of Immunology (Baltimore, Md. : 1950). 185: 6608-16. PMID 21048109 DOI: 10.4049/Jimmunol.1001768 |
0.499 |
|
| Show low-probability matches. |